More info
Active ingredients
Naftifine
Release form
Cream
Composition
Active ingredient: Naftifine (Naftifine) Active ingredient concentration (mg): 10
Pharmacological effect
Antifungal drug for external use of the group allylaminov. The mechanism of action is associated with the inhibition of the synthesis of squalene-2,3-epoxidase, which leads to a decrease in the formation of ergosterol, which is part of the cell wall of the fungus. (Aspergillus spp.) And other fungi (Sporotrix schenckii). With respect to dermatophytes and aspergillus, naftifine is fungicidal. With respect to yeast fungi, it exhibits fungicidal or fungistatic activity depending on the strain of the microorganism. The drug has an antibacterial effect against gram-positive and gram-negative microorganisms that can cause secondary bacterial infections. The drug has an anti-inflammatory effect, which contributes to the rapid disappearance of the symptoms of inflammation, especially itching.
Pharmacokinetics
Absorption and distribution When applied externally, naftifine penetrates well into different layers of the skin, reaching concentrations sufficient to effect the antifungal effect. After application of systemic absorption to the skin, less than 6% of the active substance is exposed. Metabolism and excretionThe amount absorbed is partially metabolized and excreted by the kidneys and through the intestines. T1 / 2 is 2-3 days.
Indications
Fungal infections of the skin and skin folds (tinea corporis, tinea inguinalis), incl. interdigital mycoses (tinea manum, tinea pedum); nail fungal infections (onychomycosis); skin candidiasis; pityriasis versicolor; dermatomycosis (with or without itching).
Contraindications
Pregnancy (safety and efficacy not determined); lactation period (safety and efficacy not determined); Hypersensitivity to naftifine, benzyl alcohol or other components of the drug.
Precautionary measures
Do not exceed the recommended dose. With care: children's age (experience of clinical use is limited).
Use during pregnancy and lactation
Use of the drug Exoderil during pregnancy and lactation is contraindicated (safety and efficacy not determined).
Dosage and administration
Exoderil should be applied to the affected surface of the skin and adjacent areas 1 time / day, after thorough cleaning and drying, seizing approximately 1 cm of a healthy area of skin along the edges of the affected area. The duration of treatment for ringworms is 2-4 weeks (up to 8 weeks), with candidiasis - 4 weeks. When onychomycosis, before the first application of the cream, it is necessary to remove the affected part of the nail as much as possible with scissors and a nail file. The drug should be used 2 times / day, the duration of treatment - up to 6 months. To prevent recurrence of infection, therapy should be carried out for at least 2 weeks after the disappearance of the clinical symptoms.
Side effects
Local reactions: in some cases - dry skin, hyperemia, burning. Side effects are reversible and do not require discontinuation of therapy.
Overdose
No cases of overdose have been reported.
Interaction with other drugs
No marked drug interaction Exoderil with other drugs.
special instructions
The drug is not intended for use in ophthalmology. Contact with the drug should be avoided. Special measures for the destruction of the drug are not required. Effect on the ability to drive vehicles and control mechanisms The drug does not adversely affect the ability to drive vehicles and perform other activities that require concentration and psychomotor speed.